Navigation Links
Amarantus BioSciences to Present at the 2012 National Investment Banking Association Conference in New Orleans
Date:2/23/2012

SUNNYVALE, Calif., Feb. 23, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing MANF, a first-in-class disease–modifying therapeutic protein, today announced that Gerald E. Commissiong, President and CEO, will present the Company's updated business plan at the 2012 National Investment Banking Association (NIBA) conference on Thursday, February 23, 2012 at 12:25pm CST at Le Pavillon Hotel in New Orleans, LA. Mr. Commissiong will also be holding 1-on-1 meetings with investors.

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a development-stage biotechnology company founded in January 2008.  The Company has a focus on developing certain biologics and biomarkers surrounding the intellectual property and proprietary technologies it owns and has rights to for the treatment and diagnosis of Parkinson's disease and other human diseases.  The Company owns the intellectual property rights to an anti-apoptotic therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"), and owns an inventory of 88 cell lines referred to as "PhenoGuard Cell Lines" from which MANF was discovered. The Company also has a license to the NuroPro™ diagnostic test for Parkinson's disease from Power3 Medical Products. For further information please visit www.amarantus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications, advantages presented by Amarantus' PhenoGuard technology, and/or possible benefits of the NuroPro™ diagnostic platform, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.

MEDIA CONTACTS:
IR Sense
Remy Bernarda
Remy@irsense.com
415.203.6386


'/>"/>
SOURCE Amarantus BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes
2. Amarillo Biosciences Appoints Dr. Stephen Chen as Chairman and CEO
3. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
4. GeneLink Biosciences Completes Sale of GeneWize Life Sciences
5. Ambit Biosciences to Present at Two Upcoming Investor Conferences
6. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
7. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
8. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
9. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
10. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
11. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... During a two ... into a viable company, CereScan’s CEO, John Kelley, joined other Denver business leaders ... and mentor in the Denver area business community, shared his top fundamental learnings ...
(Date:4/29/2016)... ... April 29, 2016 , ... Intelligent Implant Systems announced today that ... 510(k) for sale in the United States. These components expand the capabilities of ... With one-level sales beginning in October of 2015, the company has seen significant sales ...
(Date:4/28/2016)... , April 28, 2016 ... Stirling, and Brayton Cryocoolers), Service (Technical Support, Product Repairs ... Geography - Global Forecast to 2022", published by MarketsandMarkets, ... 2.94 Billion by 2022, at a CAGR of 7.29% ... market data Tables and 94 Figures spread through 159 ...
(Date:4/28/2016)... Conn. (PRWEB) , ... April 28, 2016 , ... ... financing and ongoing support for Connecticut's innovative, growing companies, today announced the launch ... health and financial technology (fintech) companies. , “VentureClash looks to attract ...
Breaking Biology Technology:
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
(Date:3/31/2016)... BOCA RATON, Florida , March 31, 2016 /PRNewswire/ ... LEGX ) ("LegacyXChange" or the "Company") ... presentation for potential users of its soon to be ... The video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also ... by the use of DNA technology to an industry ...
(Date:3/22/2016)... , March 22, 2016 ... report "Electronic Sensors Market for Consumer Industry by Type ... Others), Application (Communication & IT, Entertainment, Home ... Global Forecast to 2022", published by MarketsandMarkets, ... expected to reach USD 26.76 Billion by ...
Breaking Biology News(10 mins):